IMRICOR (IMR) has The world’s first commercially available MRI compatible catheter ablation devices.
IMR's Vision MR Ablation Catheter (Cardiac ablation a US$4B market) brings tremendous value proposition to the treatment of heart arrhythmias , in that in comparison to conventional x-ray approach, it (i) reduces likelihood of repeat procedures due to ability to determine permanency of lesions (ii) improved heart visualisation compared to x-ray imaging (iii) reduced per procedure costs (iv) reduced procedure time and (v) no radiation or risk of radiation related side effects or injuries.
I believe IMR will follow the footsteps of our PNV and NAN to become major health innovation companies with a global market share - at a market cap of $286m it is still at its early stages of growth, the next catalyst is likely to come from FDA approval expected in the coming year.
PNV and NAN are both having a valuation of close to $2B. IMR shares a common feature with these two successful companies with world stage presence- a robust first-in-breed IP and a globally scalable and much needed value proposition offered by its solutions.
IMO IMR is a Long Term Buy and especially on weakness. Imricor has designed Vision-MR Ablation Catheter to work under MRI guidance
The company said that it has designed the new Vision-MR Ablation Catheter to work under real-time MRI guidance. Imricor claims to be the first company to offer cardiac ablation devices for the use in an MRI environment.
Its new ablation catheter is said to offer superior outcomes along with faster and safer treatment than conventional procedures performed using x-ray guided catheters.
Imricor will provide hospitals and clinics with capital and consumable products for interventional cardiac magnetic resonance imaging (iCMR) labs, where ablation procedures are performed using its new Vision-MR Ablation Catheter.
The company has signed agreements with numerous sites for the sale of its products. Equipped with Advantage-MR systems, the sites are ready to start procedures, with the present CE mark approval.
Imricor marketing director Nick Twohy said: “The future of cardiac ablation therapy is in MR-guidance and this product launch is the first step towards a new standard of care. We look forward to partnering with healthcare professionals to offer a new treatment option for patients who suffer from arrhythmias.”
